SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.
The 1Bio™AI-Acute system uses only bedside-recorded vital signs—pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure—to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient's general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.
WHY IT MATTERS
"Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care," said Dr. Gurpreet Singh, CEO and Founder of Respiree.
The 1Bio™AI-Acute is readily available to healthcare professionals through Respiree's 1Bio™ platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio™AI-Acute toolbox, the 1Bio™platform, and the RS001 wearable are all now approved by HSA.
With the HSA approval for the 1Bio™AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States, in the coming months.
HSA's approval of the 1Bio™AI-Acute toolbox follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings.
About Respiree
Respiree™ is an AI/ML health tech company building clinically-validated AI for managing disease progression. Respiree™ products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION
NORWALK, Conn., May 27, 2026 /PRNewswire/ -- GameChange Solar, a leading global supplier of solar tracker and fixed-tilt racking technology, announced compatibility between its Genius Tracker™ platform and SUNPURE's Saturn module installation system, supporting increased automation in utility-scale solar construction.
SUNPURE's Saturn system is designed to automate module installation across varying site conditions, including uneven and undulating terrain. The system is capable of installing 600-1,000 modules per day while helping reduce labor intensity and improving installation efficiency on large-scale solar projects.
The compatibility between SUNPURE's Saturn system and GameChange Solar's Genius Tracker™ platform enables developers and EPCs to integrate automated module installation into tracker-based solar projects more efficiently.
Click here for video: Introducing Saturn Robot for Utility-Scale Solar Projects
"With labor shortages continuing to impact utility-scale solar construction, automation will play an important role in how the industry shifts. Compatibility between tracker systems and automated installation technologies is an important step toward improving execution speed and reducing labor intensity on large-scale projects. SUNPURE has developed a strong solution with the Saturn system, and its compatibility with the Genius Tracker platform reinforces the flexibility of our tracker design across varying project conditions," said Phil Vyhanek, CEO, GameChange Solar.
To date, SUNPURE's Saturn system has supported the installation of more than 2.36 GW of solar capacity globally and is currently available in select international markets. Availability in the United States is expected to begin in Q1 2027.
"GameChange Solar is one of the leading global tracker suppliers and we are pleased to announce compatibility between their Genius Tracker™ platform and SUNPURE's Saturn module installation system. As adoption of automated construction technologies continues to grow, compatibility between installation systems and tracker technologies will play an important role in efficient project execution," said Zoe Hu, CEO, SUNPURE.
About GameChange Solar
GameChange Solar is one of the top three global providers of solar tracker solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. We have delivered over 63 GW of solar tracker and fixed tilt systems that combine fast installation, bankable quality, and unbeatable value through superior engineering, innovative design, and high-volume manufacturing. Our products enable solar panels at power plants to follow the sun's movement across the sky and optimize plant performance while protecting the array from damaging weather conditions.
For more information about GameChange Solar and its solar tracking solutions, visit www.gamechangesolar.com
Media Contact:
Lisa Andrews
Director of Marketing, GameChange Solar
lisa.andrews@gamechangesolar.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GameChange Solar Announces Compatibility Between Genius Tracker™ and SUNPURE's Saturn Module Installation System
